For the treatment regarding the three mi-RNAs in ovarian cancer associated fibroblasts, I tried to figure out downstream targets by which these epigenetic changes of mi-RNAs in CAFs induce epithelial to mesenchymal transition of cancer cells. I proposed a few possible pathways, although these are likely far more complicated, and there are likely many more that I did not cover. What makes mi-RNAs interesting is that because they are so short, approximately 20 bases in length, they often have binding specificity for thousands of genes. This means that treatment involving mi-RNAs usually evolves from an observational study about mi-RNA dysregulation, and the reversal of that phenotype having anti-cancer effects. With mi-RNA treatment, it is often the case that it is discovered that reversal of the phenotype is effective in treating cancer, without figuring out exactly why, because the possibilities are so vast.
Recent comments